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INTRODUCTION
Organophosphorous (OP)   pesticide  self-poisoning  is  estimated   to
kill around   two lakhs   population  per  year, largely  in  pacific  asian   region ,
majority  of incidences  takes  place  in  rural  populations  and  is mostly  due
to  impulsion.  In  western  population  the  scenario  is different  that  is  more
incidence  of  poisoning  with  drugs  takes  place.
 In  India  the  mortality  is  around  one  fourth  to  one  fifth;  but in
western  it  is  only less  than  one  percent(1). Even developed countries are
prone to military or terrorist attacks with nerve agent OP compounds. 
     The main mechanism of action of all OPs is that they inhibit the enzyme
acetyl  cholinesterase.  Majority  of  the  mortality  is  due  to  cardiorespiratory
compromise. But the clinical manifestations vary with type of insecticide and
amount of insecticide consumed.
      In a clinical study 38 percent of patients require intubation for respiratory
compromise  following  that  the  death  rate  was  also  high (2).  If  cardiac
complications are not recognised early it can be fatal. 
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The exact pathogenesis of cardiac complications has not yet been defined.
A few important studies have been carried out both in India and abroad to study
the  cardiac  complications  and  electrocardiographic  changes  in
organophosphorous poisoning.
     The current study was carried out to understand the cardiac manifestations of
organophosphorous poisoning with special  reference to cardiac enzymes and
ECG changes.
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                               REVIEW OF LITERATURE
     In organophosphorous intoxicated patients, cardiac manifestations are
not uncommon. In most patients the ECG may show, simple effects to lethal
changes.  These  includes   sinus  tachycardia,  repolarisation  abnormalities
including ST segment  deviation and  T wave abnormalities ,Q-T prolongation,
arrhythmias and A-V blocks(3) .
 The mechanisms of   cardiotoxicity are not clearly understood. Apart
from direct toxic effects of the OP compounds, dyselectrolemia, and acidosis
are mainly due to increased sympathetic and/or parasympathetic activity are the
reasons behind   myocardial damage in organophosphorous intoxication. The
reported  prevalence  of  various  electrocardiaographical  changes  in  OP
compound is 89.1 % (3).
 Myocardial damage is caused by both sympathetic and parasympathetic
over  activity  (4).  Yasue et  al  in  1974(5) discovered that  parasympathetic  over
activity leads to coronary artery spasm; following that Horio et al (6) injected
acetylcholine  into  intracoronary  vessels  and  demonstrated  coronary
vasoconstriction. 
Kiss  and  Fazekas  identified  transient  myocardial  infarction  in  five
patients among the 168 cases included in a study (7). Diffuse myocardial damage
was found at autopsy in two cases of  Malathion intoxication (8).
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        Kathi et al conducted a study in 37 patients (3) for a 3 year period of cardiac
complication following organophosphorous intoxication; out of 37, 62.5% that
is 23 of 37 patients had cardiovascular injury, of which 29.7% that is 11 out of
37 developed electrocardiographic changes suggestive of injury to myocardium
(ST-T Changes); three out of 37 died, that is 8.1% (3/37).
CP Dalvi et al  (7) studied the correlation of electrocardiographic changes
in organophosphorous poisoning with its prognosis.  Abnormal ST-T changes
and progressive fall in voltage and or low voltage were the commonest ECG
changes encountered. These occurred significantly more often in patients with
moderate  or  severe  poisoning  (p<  0.001).  The  17  patients  (5  moderate,  12
severe) with a combination of these ECG abnormalities required higher doses of
atropine (mean 30 mg) and, in the 12 who survived, the ECG took longer (mean
5.5 days) to normalize(despite normal clinical  recovery rate)  as compared to
other cases. All fatal cases in the study had both these ECG changes.
   WANG  Jian-dong  et  al (9)  studied  the  dynamic  changes  of  cardiac
enzymes and the acute poisoning with organophosphorous in  Department  of
Emergency,  Sichuan  Provicial  People's  Hospital.  Fasting  serum  level  of
troponin T and cardiac enzymes (CK-MB, CK, AST, and LDH) in 92 patients
with  acute  organophosphorous  poisoning  (AOPP)  were  measured  after
poisoning 1,2,3,5 and 7 days, and were measured one time in normal control
group  as  well.  There  was  an  increase  of  different  levels  in  troponin  T  and
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cardiac enzymes along with the degree of  (AOPP). They concluded that  the
level of cardiac troponin T and cardiac enzymes in patients with AOPP may be
as useful markers of degree of poisoning and prognosis.
       GUO  Ya-ying  et  al  conducted  a  study  at  the  People's  Hospital  of
Yingshang, Anhui. They studied the applied value of serum cardiac troponin
T(cTnT)  for diagnosing myocardial lesion in the acute organic phosphorous
pesticide  poisoning(AOPP). The serum cTnT and CK-MB were significantly
higher than that in control group and increased with the degree of poisoning.
They concluded that the level of serum cTnT increase significantly with the
serious degree of AOPP and was sensitive marker of myocardial injury.
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           HISTORY OF ORGANOPHOSPHORUS COMPOUNDS
Two men first involved in research of OPC compounds were Jean Louis 
Lssaigne and Philippe de Clermont (1854).cholinergic effects of OPC was first 
described by German chemist Willy Lange and his graduate student, Gerdevon 
Krueger(1932). 
In  World  War  II  Germans  used  the  first  OP  compound  tetraethyl
pyrophosphate because of scarcity of nicotine. Nicotine is a botanic insecticide
used  in  wars.  In  1854  tetraethyl  pyrophosphate  was  first  produced.  Then
Germans discovered the OP nerve agents “soman, sarin, tabun” and used them
in World War II. They discovered it’s lethal to humans.
 Wide  production  of  OP compounds  occurred  after  World  War  II  by
Americans with the help of Schrader, s lab. Parathion came into market first and
then  Malathion  followed  by  Azinphosmethyl.  In  1970  Heptachlor,  DDT,
Dieldrin  are  banned.  Subsequently  these  organophosphorous  compounds
became popular. The mechanism of action of OP compounds was discovered
after mass intoxication and suicidal attempts like Jamaican ginger palsy (1930).
Tokyo subway incident which was happened in 1995 was due to a religious
sector  (Aum  Shinrikyo)  used  sarin  to  intoxicate  people.  In  India  also  at
Margrawa  in  2005  at  a  social  event  due  to  accidental  ingestion  of  ethion
contaminated food, 15 people were intoxicated.
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STRUCTURE OF ORGANOPHOSPHATES
Organophosphates are complexly structured compounds with few same
chemical features.  The structure of organophosphates includes a phosphorus
molecule with a double bond to sulfur (P=S) or oxygen (P=O) and two organic
side chains (R1 and R2), and with a leaving group (additional side chain- X). 
The group which  leaves  is  peculiar  to  the  individual  OP and may be
cyanide,  thiocyanate,  phosphate,  halide,  thiophenoxy,  and  carbamate  or
phenoxy group. The R1, R2 groups may be alkyl / aryl groups and, in most of
the common OP compounds, are either two ethyl or two methyl ester groups
which forms the diethyl (diethoxy) /dimethyl (dimethoxy) OP compounds. 
7
Chemical Classification of Representative Organophosphorous 
Compounds
Group A, X = halogen, cyanide, or thiocyanate leaving group;
 group B, X = alkylthio, arylthio, alkoxy, or aryloxy leaving group;
 group C, thionophosphorus or thio-thionophosphorus compounds; 
group D, pyrophosphates and similar compounds; 
group E, quaternary ammonium leaving group. 
R1 can be an alkyl  (phosphonates),  alkoxy (phosphorates)  or  an alkylamino
(phosphoramidates) group.
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EPIDEMIOLOGY
a)Global Status:
 More than three fourth of pesticide related hospital admissions are due to
organophosphate compounds and are associated with lethal human effects (10).
Use  of  organophosphate  insecticides  increases  as  compared  to
organochlorides like DDT because of their unstable nature which ends in rapid
hydrolysis  and  reduced  accumulation  in  environment,  because  of  the  easy
availability leads to higher incidence of human toxicities. 
In  US the environmental  protection agency  estimated that  more than
three thousand admissions were occurred due to insecticide poisoning, and the
mortality rate was 10 percent in adults and 50 percent in children  in 1970s(11)
American Association of Poison Control Centres in 1983 estimated that
total no of poisoning with insecticides were around 77,000, of which 33,000
were due to OP compounds. 
 In  1990 WHO published  (12) from the available  data that  thirty lakhs
intoxications due to pesticides took place, out of that 2 lakhs twenty thousand
people  died.  This  was  the  first  publication  by WHO.  Subsequently  in  2001
WHO published that eight lakhs forty nine thousand people die due to pesticide
poisoning yearly(13)  .
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So the trend shows increasing incidence of suicidal tendency globally, out
of this majority occurred in Asian countries with in rural population that is more
than 60 percentage of mortality  (14). In suicidal methods incidence of pesticide
poisoning is higher than hanging and any other forms of suicidal nature. 
 Bangladesh  national  data  recently  estimated  around  14  percent  of
mortality in females with the age range from 10 to 50 were the result of self
harm mainly because of pesticide intoxications (15) .
In Sri Lankan Island at the period of 1995 most common cause leading to
nursing  home  mortality  was  due  to  poisoning  with  pesticides  especially  in
people who were pertaining to rural population (16) .
 Globally  especially  in  Asian  countries,  due  to  easy  availability  of
pesticides because majority of people depends on agriculture for survival, cause
of self  harm is mainly due to these agents.  This predisposes the health care
staffs at risk of exposure to these agents, which can cause health risk.
b)national status
One fourth of nation’s GDP is from agriculture, so it’s one of the major
contributions to economy. In India we are widely using pesticides. In Indian
pesticide industry there are around 40 large companies and 400 formulators. 
These highly hazardous products are available with ease to Indian people
because  of  the  marketing  system  is  fragmented  and  also  there  is  minimal
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awareness among people regarding the adverse health outcomes. But outside
India the global statistics is different, 60% of the marketing is done by five top
multinational branded companies. 
c)Toxic exposure to pesticides can occur at many levels
 1)  Before  spraying–  because  of  easy  access  for  children,  lack  of
adequate labelling
 2)  During mixing
 3)  During spraying and
 4)  After  spraying  operations,  Spray  operators  and  bystanders  can  be
affected.  Low cost and easy availability of  highly  hazardous  pesticides  at
hand increased  the incidence  of  intentional  pesticide  poisonings (17) .
 Number of cases of pesticide poisoning occurring in India per year has
been estimated by   G. Ravi et  al  (2007) is around 76 000, and it  is higher
numbers than NCRB. In the same year Gunell et al, calculate that the number of
intentional cases as 1.26 million per year  (18) .
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PATHOPHYSIOLOGY OF TOXICITY
OPC COMPOUNDS WITH MODERATE AND HIGH TOXICITY
HIGHLY TOXIC MODERATELY TOXIC
Phosphamidon (dimecron) Fenthion (baytex,entex)
Ethyl parathion (folidol-lipid soluble) Malathion (finit)
Chlorothiophos (celathion) Fenitrothion (tik-20 )
Carbophenothion  (trithion-lipid
soluble)
Diazenon  (spectacide)
Methyl parathion (moon bug liquid) Temephos (abate)
  Inhibition of acetyl cholinesterase by OPC 
Organophosphates  bind  and  inhibit  acetyl  cholinesterase  enzyme  thereby
producing toxic effects. It binds at the active serine site. Due to inhibition of
enzyme  acetylcholine  accumulates  at  peripheral  and  central  muscaranic  and
nicotinic  receptors.  Accumulated  acetylcholine  at  nerve  terminals,  initially
stimulates,  and  then  paralyzes  neurotransmission.  Acetyl  cholinesterase
physiologically breaks acetylcholine by hydrolysis into two inactive substances
that  are  choline  and  acetic  acid.  Because  catabolism  of  acetylcholine,  its
availability at synaptic junctions is reduced, and also choline is available for
reuptake and reproduction of acetylcholine. 
Due  to  inhibition  of  acetyl  cholinesterase  number  of  acetylcholine
molecule is high at neuromuscular junction which leads to excitatory effect on
post  synaptic junction. When acetyl  cholinesterase is  inhibited, acetylcholine
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cannot be broken down and accumulates at the nerve or myoneural terminal,
leading initial postsynaptic excitation followed by inhibition at neuromuscular
junction. Because of depolarizing blockade at postsynaptic junction inhibition
happens.  But  RBC  membrane  also  exhibits  cholinesterase  activity  and  it’s
called as RBC cholinesterase. 
      In serum and liver there is butyryl or pseudo cholinesterase which plays
major role in xenobiotic metabolism. Since RBC acetyl cholinesterase activity
resembles closely with neuronal acetyl cholinesterase it can be taken to measure
the  physiological  activity  of  cholinesterase  enzyme  (19).  But  measuring
butyrylcholinesterase is a simple technique; this is most widely performed in
health care facilities.
 STRUCTURE OF ACETYL CHOLINESTERASE AND MECHANISM 
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  Is  has  a  pit  with  a  catalytic  region  and  serine  binding  region
1)organophosphorous axon which is electrophilic binds(reversible) to the serine
active region forming a complex (michalis-menton )
2) After that rapid phosphorylation of the serine residue happens.
3) Then release of leaving group of organophosphorous happens (X) 
4) Now the organophosphorous is covalently bound to the enzyme pit.
5) After this conformational change in the enzyme occurs. 
6)  After  the  conformational  change  acetylcholine  cannot  bind  to  the  active
region of the enzyme.
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7) So catalysis of acetylcholine is inhibited  (20)  .
 Aging and reactivation of acetyl cholinesterase
 After these reactions the phosphorylated enzyme will undergo into two
different reactions
  a) The enzyme can be irreversibly bound or aged 
 b) Inactivated by dealkylation which leads to cleavage of one of the R groups,
because of which the substituted phosphoric acid residue is firmly attached to
the enzyme site. 
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 Aging and reactivation
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  Depends on the specific organophosphorous the aging process varies. 
 Reactivation of acetyl cholinesterase
Alternately  enzyme  reactivation  can  happen  when  serine
organophosphorous bond is hydrolyzed. Reactivation of enzyme happens faster
when  nucleophilic  oxime  is  added.  Or  reactivation  may  be  dead  slow  for
organophosphates which contains di-ethyl group. 
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 Depending  upon  which  R  group  is  attached  the  rate  of  reactivation
process or aging process depends. When the R chain is smaller the reactivation
is fast, when the R chain is branched due to steric hindrance it increases the
bond stability so reactivation is delayed. 
To  support  this  dimethyl  organophorous  compounds  which  are
phosphorylated will  undergo rapid reactivation than di-ethyl OP compounds,
dimethyl  OPs have significantly  faster  rates  of  spontaneous  reactivation and
aging  (half  lives  of  about  0.7  hours  and  about  3.7  hours,  respectively)than
diethyl OPs (half-lives of 31 hours and 33 hours, respectively).  
Inspite  aging  is  rapid  for  di-methyl  OP  compounds,  they  are  more
resistant to oximes especially pralidoxime.  The need of oximes to reactivate
Di-ethyl organophosphorous compounds are more (21) .
Inspite  of  all  these  things,  the  enzyme  will  not  be  a  candidate  for
reactivation  either  by  endogenous  hydrolysis  or  oxime  treatment  when  it  is
aged. The inhibition of acetylcholinesterase does not depends on equilibrium
reaction  and  is  mostly  depends  on  the  concentration  of  organophosphorous
present at the enzyme level. 
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What happens when a person is exposed to OPC? 
The organophosphates starts forming oxons, at one time there is a nadir in
oxon  concentration,  then  it  diminishes;  there  is  also  a  decline  in
organophosphorous concentration. Inspite of decreasing serum levels of oxons
and OP compounds the inhibiting action will be continued because of covalent
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bonding.
Physiologically, people who are exposed low level of functioning enzyme
is left without binding.
 Once this upper limit is reached, removal of circulating OP not even
enhances  the  functionality  of  acetylcholinesterase.  Then  the  catalysis  of
acetylcholinesterase is only based on restoration of uninhibited enzyme.
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      Recovery may be fast with few di-methoxy organophosphorous compounds
due to reactivation by endogenous route, in these cases rapid decontamination
can speed the patient’s recovery, but dimethoatethe is an exception. 
     Reactivation by oximes 
 The tendency of oximes to reactivate the enzyme is based on several factors
1) Organophosphorous structure 
2) Duration of oxime at the active region
3) Concentration of the oxime. 
 4) Transient complex is formed during the reactivation process (oximes with
activated acetylcholinesterase)  
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5) This transient complex follows saturation kinetics
6) So reactivation of acetylcholinesterase does not occur after saturation. 
7) Oxime while interacting with OPC, it removes the organophosphorous from
the  enzymatic  site,  meanwhile  it  forms  an  oxime  complex  which  is
phosphorylated.
8)  This  phosphorylated  complex  strongly  inhibits  the  enzyme
acetylcholinesterase.
 9) In addition to this oximes itself  has the ability to inhibit 
acetylcholinesterase. 
10) The overall result is even with pralidoxime or other oxime therapy there
will  be  unrecognized  mild  elevation of  blocked  acetylcholinesterase  enzyme
and there may be a clinical worsening (21)   .
11) Phosphorylated oxime complex formed with PAM will disappear quickly
since because of unstable nature, and there will not be any clinical impacts.  So
there is no significant variation.
12) If the oximes combines with acetylcholinesterase and forms phosphorylated
oximes, and emits the OPC, due to the stochiometric property its reaction takes
place with one molecule of enzyme only (personal communication, Peter Eyer,
2006).
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 13) Stable phosphorylated oxime is produced by Obidoxime,so, so it can have
clinical impacts, but this is yet to be studied in humans (22)  .
 Delayed toxicity 
  Fenthion like  OPC has  some properties  which  can lead to  prolonged and
delayed toxicity in humans, inspite of oxime treatment. The mechanisms behind
this are
a) High lipid solubility
b) Prolonged elimination 
c) Requirement of bioactivation
d) If exposure amount is high. 
e) As the organophosphorous is released from fatty tissues continuously, the
newly regenerated acetylcholinesterase is again inhibited.
PROPERTIES OF ANTI-CHOLINESTERASE
 Pharmacological properties of anti-ChE agents are predicted by
 a) Identifying the sites where acetylcholine is released by nerve stimulation,
b) Amount of nerve impulse activity
c) Acetylcholine response in the tissues which effects.
The anti-cholinesterase can lead to the bellow mentioned outcomes:
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(1)  Muscaranic stimulation of autonomic structures.
(2) Initial excitation and following inhibition of skeletal muscle and autonomic
ganglions due to action on nicotinic receptor and
 (3) Cholinergic receptor excitation followed by occasional inhibition of central
nervous system.
 Almost all the above mentioned effects will be seen after lethal dose of
anti-ChE  agents.  But  when  the  doses  are  small,  particularly  those  used
therapeutically, several modifying factors are significant. 
Generally  quaternary  ammonium  compound  does  not  enter  into  cells
through cell membrane easily. 
So these are not absorbed by the gut / dermis and the BBB prevents it to
enter into CNS after moderate doses. On the other hand, such compounds act
preferentially at the neuromuscular junctions of skeletal muscle, exerting their
action both as anti-ChE agents and as direct agonists.
 They  have  comparatively  less  effect  at  autonomic  effector  sites  and
ganglia.
The opposite happens with fat soluble anti-cholinesterase, they are readily
absorbed following oral ingestion and at the same time it has its action at central
as  well  as  peripheral  regions,  and  they  may  dissolve  in  fatty  tissues  for
prolonged  duration.  Lipid-soluble  organophosphorous  agents  also  are  well
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adsorbed  through the  epidermis,  and  the  agents  with  evaporating  nature  are
easily transferred readily across the alveoli of lung.
MYOCARDIAL INJURY IN OPC
The mechanism of which OPC induced myocardial  damage accordance with
Ludomirsky et al has got 3 levels
 1) Short duration of raised sympathetic activity presenting with period of
intense increase in sympathetic tone manifested by sinus tachycardia;
(2) second phase that is extended parasympathetic tone featured by  ST
segment -T wave changes, trio ventricular blocks of any degree ,altered  rhythm
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pattern  and  even  VF   in  electrocardiography  and  also  associated  with
hypoxemia .
(3) Third level with the following ECG changes that is prolonged  QT ,
pleomorphic tachycardia and clinically as  cardiac arrest  are specific. 
Appearance of 3rd level  changes can happen either as early following
poisoning  or  at  times  takes  many  days  following  intoxication  even  after
disappearance of signs and symptoms of intoxication. 
Several factors are there behind arrhythmias in later parts of intoxication.
In fact there is a composite histopathological and physiological influence with
clinical and laboratory features. 
It is obvious that OPC can cause direct cardiac injury.
    Marosi  et  al,  postulated  that  the  electrophysiological  and  pathological
alterations are associated with intensity of poisoning, not with reduced activity
of enzyme or atropine. In animal studies it is documented that following OPC
exposure electrocardiographic changes happens first followed by reduction in
cholinesterase activity and these changes are dose related. So it is concluded
that QT prolongation in OPC is due to direct toxicity to myocardium, and it is
unrelated to cholinergic stimulation. 
       Some literature shows that due to sustained action of Ach at vagal nerve
endings, pathological damage to cardiac muscle happens 
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The  heart  musculature  is  innervated  by  autonomic  nervous  system
through sympathetic as well as sympatholytic nerves. Acute OPC intoxication
deforms the function of ANS, causing in coordination which in turn leads to
cardiotoxicity
   There are studies that suggest that the morphologic damage can be caused by
continuous vagus nerve stimulation (due to the liberated acetylcholine).
     Man-mug et  al  postulated altered T waves and extra systolic pattern in
electrocardiography in described in dogs with stimulation of vagal nerve.   
 Post-mortems studies in animals resulted in cardiac infarcts in papillary
muscle and other areas & also dark, mottled cardiac tissue. 
   The severity of cardiac injury   corresponds with the stimulated time by
Ach  through  vagus.  Atropine  treated  animals  lived  two  folds  higher  than
untreated ones; the atropine given animals also exhibited no cardiac injury.
   Hall et al study postulated that cardiac injury is through Ach, which in
turn caused by vagal  stimulation.  The above mentioned previous study goes
hand in hand, with Hall et al study. 
     Brief administration of NA in rabbits, cats & dogs 3) leads to catecholamine
release which leads to cardiac injury. This confirms that initial sympathetic over
activity in OPC poisoning which cause cardiac compromise. Studies show that
this  injury  can  be  avoided  by  administering  sympathetic  blockers.
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Parasympathetic  stimulation is  also plays a  role  in  disease pathology this  is
similar to mechanism suggested by Gebbers et al’ for myopathy.
 It is postulated that acetylcholine injection into coronary vasculature of
acetylcholine  causes  vasoconstriction  in  a  greater  number  of  people  with
healthy  & atherosclerotic  coronary  vessels.  So  in  addition  to  hypoxemia  as
previously coated, with generation of  oxygen free radicals (which can cause
necrosis  of  myocardium)  &  imbalance  in  perfusion  to  coronary  vessels  is
caused by hypoxemia and sympathetic stimulation, are the possible causes for
myocardial  injury  in  OPC  poisoning  (in  the  long  run  it  may  lead  to
cardiomyopathy & further sequlae ) cause for high incidence of ST-T changes
in ECG in  acute stage is also explained by the above mechanism. 
   But we are not able to substantiate that why these ST-T changes are
lasts  longer  than  symptoms  subsides.  Though  its  an  event  associated  with
compromised perfusion, which is an acute event, we are not able to explain why
the ST-T changes persists, unless we conclude it as a chronic cardiac pathology.
     Electro chemical mechanism of cardiac injury 
The basic pathology is Ach binds with its receptors it releases calcium
ions. In OPC poisoning due to excessive availability of Ach, which binds to its
receptors, induces a mass inflow of calcium ions into cytosol, which leads to
abundant depolarization of, the muscle end-plates, leads to muscular damage. 
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        Salpeter et alh8 studied the effect of acetylcholinesterase with regarding to
muscle. He postulated that acetylcholinesterase by inhibiting the action of Ach
in skeletal  muscles  it  diminishes  the  stimulation rate  ,thereby protecting the
myocyte from diminishing energy at early stages to delaying myopathy in long
run. 
 From the point of view that, cardiac arrhythmias which are delayed in
onset  are  treated  with  IV Mg –sulfate.  It  strongly  favours  that  distortion  of
calcium  ion  balance  at  cellular  level  has  a  major  role  in  the  pathology  of
cardiomyopathy in OPC poisoning. 
  Torsades de pointes 
The exaxt pathophysiology is not clearly known.  But during later part of
OPC poisoning, main pathology involved is a combination of degenerative and
regenerative, so it is concluded that there is focal/ multifocal areas of cardiac
muscle injury interspersed with normally functioning cardiac tissue, this can be
the  reason  which  potentially  leads  to  re-entry  &  heterogonous  areas  of
depolarization & repolarization, and that this may result in arrhythmia.
     In whom delayed cardiac complication develops?
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 There is no specific time delay between intoxication and development of
cardiomyopathy, it is practically not predictable. It is predicted in few OPCs,
especially with nerve gas agent soman, which was used as warfare agent.  In
soman poisoning reactivation of enzyme takes place for a prolonged duration &
because of rapid aging reactivation of the enzyme is limited.
But generally it seems that  when the severity of intoxication is more  the
patients are more prone for delayed cardiac complications like arrhythmias and
the causes are complicated and many as mentioned above.
    
  Uncommon and unpredicted late cardiotoxicity can happen even after
days or weeks, probable mechanisms postulated are
 (a) Direct cardiac injury due to poison itself 
(b)  Hypoxemia & acidosis &dyselectrolemia; 
(c) Reperfusion recovery and healing of injured cardiac tissue 
(d) Autonomic pathology & insufficiency.  
 Roth et al described that after OPC intoxication there is abundance in
FFA which can lead to arrhythmogenic potential. At last, cholinergic stimulus
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which  induces  sympathetic  activity  at  postganglionic  fibres,  compensatory
reflexes, and has toxic adrenergic drive to the myocardium. 
CREATINE PHOSPHOKINASE MB
    CREATINE KINASE —There are two isoforms of  creatinine kinase ,made
by M and B chain dimers .
Three combinations are present MM, MB, and BB. They are present in
cytoplasm. It contributes to the release of high-energy phosphates into and out
of mitochondria.
Distribution of CK
Various tissues exhibit CK isoenzyme activity. But fraction of CK-MB
present in cardiac tissue is greater than other tissues. But B chain is also present
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in  skeletal  muscle,  in  some  tissues  the  percentage  goes  by  10  percent,
radioimmunoassay technique detects them easily. Skeletal muscles have more
CK/gm than myocardium.
Because of high fraction of CPK in skeletal muscles, injury to this tissue
leads to increase in MB fraction. Added to this during  regeneration of tissues
after injury results in abundant production of CK and B chain. This is supported
by marked elevation CK-MB after a long run / excessive muscle strain.
Metabolism 
Major part of CK is catabolised by local mechanism / lymphatic’s. He
above local mechanism increases local blood flow hence increase in exit of CK
into plasma.
Total CK measurements for the detection of cardiac damage 
 Because of wider distribution of CK, it  is not specific for myocardial
injury, the specificity increases with CK-MB. To consider increase in CK it
should increase at least 2 times. But in elderly people due to reduction in muscle
mass, normally it may be within lower range .In MI in these people total CK
will be in normal range but there il be a elevation in CK-MB.Because of these
total CK is not useful to detect cardiac injury. 
CK-MB fraction for diagnosis 
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CK-MB assay can be rapidly performed & simple one. Mass CK-MB is
measured by most assays; these are more sensitive than measures of activity.
Inclusion of macrokinases is avoided in mass tests.  Macrokinases    are CK
linked IgG and dimers of mitochondrial CK .But activity tests includes these
macrokinases.So  there  is  no  confounding  factors  mass  test.  Think  of
macrokinases when CK-MB is in higher range (more than 20 %) of total CK.
Specificity and sensitivity 
 CK-MB is highly specific for myocardial tissue. It  was considered as
specific marker of myocardial injury for years. After 6 hrs of cardiac injury it
starts rising but not in all patients until around 12 hours.
Increase  in  CK-MB  is  specific  to  cardiac  damage,  with  ischemic
symptoms when no damage to skeletal muscle. It returns to baseline within 36
to 48 hrs, in contrast increase in troponin, will persist up to 10 to 14 days.
Skeletal muscle damage can confound the diagnosis of an MI and cardiac
damage as CK-MB can be released, in the following situations.
• Myocardial injury after cardiopulmonary resuscitation
• Cardio version
• Defibrillation
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• Cardiac and no cardiac surgical procedures
• Blunt chest trauma with possible cardiac contusion
• Cocaine abuse 
 CK-MB has lower fraction with total CK in skeletal muscle than cardiac
muscle So percentage criteria (from 2.5 to 5 percent) is used to  to differentiate
skeletal muscle injury from myocardial injury, it increases  specificity, but at the
cost of sensitivity in patients with both skeletal & cardiac injury. 
In  peoples  with  chronic  skeletal  muscle  diseases  mostly  have  falsely
positive CK-MB when percentage criteria are implemented. The proportion of
CK which is CK-MB can be nearly 50 percent with chronic skeletal muscle
injury, like dermatomyositis  or polymyositis, because of higher synthesis of B
chain CK.
Percentage criteria will mislead in the following situations
• Hypothyroidism.
• Renal failure.
• Mixed skeletal & cardiac damage.
     Persistent rise in CK-MB occur in carcinogenic shock..But in myocarditis
CK-MB levels don’t rise mostly except in severe myocarditis.
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Elevated CK-MB with normal total CK and CK-MB/total CK ratio 
In  myocardial  damage there  will  be  a  2  fold  rise  in  total  CK with  a
proportionate elevation in CK-MB. Sometimes, there will be a rise in CK-MB
without a rise in CK; this has got a grave prognosis.
CK and coronary reperfusion 
The time to peak CK levels and the slope of CK-MB release can be used
to  assess  whether  reperfusion  happened.  In  2004  ACC/AHA  realised  that
sequential  measures  of  CK-MB can be helpful  to  support  the  occurrence of
reperfusion 
PHARMACOKINETICS OF OPC
Organophosphorous  anti-ChE  agents  with   increased  risks  of  lethal
effects have increased  vapour pressures,  highly lipid-soluble agent and liquid
in nature. Most of the agricultural insecticides are less volatile agent. They are
mainly used for  dispersal as aerosols or as dusts adsorbed to an inert, minute
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particulate matter (e.g., diazinon, malathion) Mostly the chemical compounds
are  entered  into  the  body   through  the  contact  with  moisture  i.e   skin  and
mucous membranes, by the GIT after taking food products which is fortified
with these substance, and by the lungs after inhalation(23).
Following  their  absorption,  most  organophosphorous  compounds  are
excreted from the body in the urine. Two enzymes such as Plasma and liver
esterases are needed for hydrolysis to the corresponding phosphonic acids and
phosphoric acids.
 The CYPs are responsible for converting the inactive compound to active
compound.  Phosphorothioates  compound (inactive)  containing a  phosphorus-
sulfur (thiono) bond to phosphorates (active) with a phosphorus-oxygen bond.
These  enzymes  also  play  a  Vital  role  in  the  inactivation  of  certain
organophosphorous agents.
The  organophosphorous  anti-ChE  agents  are  cleaved  by  two
enzymes families such as: 
1)paraoxonases (A-esterases) 
2)The carboxylesterases .
 These two important enzymes are present in the liver and plasma. it helps
to  hydrolyses   number  of   OPCs  by  breaking  the  PCN  bonds,  PF,
anhydride,phosphoester. The low-molecular-weight enzymes paraoxonases are
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used  for  catalysation  process  which  needs  ca2+,  whose  natural  substrate  is
unclear. Some of them have high density  lipoproteins properties which helps
for hydrolysation.
Some  enzymes  of  this  family  have  some  protective  effect  in
atherosclerosis by controlling  low density lipoprotein oxidation and leads to
protective  effect  in  atherosclerosis(24)Genetic  polymorphisms  that  govern
organophosphate  substrate  specificity  and  possible  susceptibility  to
atherosclerosis have been found(24).
Wide  variations  in  paraoxonase  activity  exist  among  animal  species.
Young animals are deficient in carboxylesterases and paraoxonases, which may
account for age-related toxicities seen in newborn animals and suspected to be a
basis for toxicity in human beings. Plasma and hepatic carboxylesterases and
plasma butyrylcholinesterase are inhibited irreversibly by organophosphorous
compounds(25)  .Their  scavenging  capacity  for  organophosphates  can  afford
partial protection against inhibition of AChE in the nervous system. 
The carboxylesterases  also  catalyze  hydrolysis  of  malathion and other
organophosphorus compounds that  contain carboxyl-ester  linkages,  rendering
them  less  active  or  inactive.  Since  carboxylesterases  are  inhibited  by
organophosphates,  toxicity  from  exposure  to  two  organophosphorous
insecticides can be synergistic.
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Absorption:
Absorption of OP compounds depends on various factors as follows
 1) Solvents present in OPC such as xylene 
 2) Emulsifying agents present in OPC  which increase absorption 
 3) Lipophilicity 
 4) Duration of contact with skin. Complete and rapid absorption of powders
takes place when the particles are fine.
    Other factors involved in absorption kinetics are 
  a) The extent of coverage of body surface.
  b) Permeability of clothing’s.
  c) Volatile property( for eg. Malathion is less volatile than dichlorvos) ,
 d) Involved skin parts (absorption of parathion is more via skin over head and
neck,axillae,and scrotal skin rather than arms and hands)
 e) Personal  hygiene.
 f) Eczema over skin and abrasions increases the absorption .  In a literature
,average amount  of dermal absorption is around two percent of  is predicted
value for parathion liquid formulations(26).
 Storage &distribution
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 Rapid accumulation of  organophosphorous compounds takes  place  in
liver, fatty tissues, salivary glands and kidney after systemic absorption. More
lipophilic substances  are  phosphorothioates  (P=S),  like bromphos , parathion
and diazinon. Less lipophilic are phosphates (P=O), like   dichlorvos. So the
more fat soluble substances are  stored heavily  in fat which leads to clinical
relapse  and  prolonged  intoxication   after   apparent   recovery  .
Organophosphorous insecticides usually cross the blood / brain barrier.
Biotransformation
 Active  cholinesterase    inhibitors  is  (P=O)   but   one  which  needs
activation  before  biologically  active  is  phosphorothioates   (P=S)  ,they  are
biologically activated  as phosphate  analogues  called as oxon. So the clinical
manifestations of phosphorothioates after OPC poisoning occurs late, since it
should be biologically activated to oxon before it acts on receptors. 
        This activation to oxon is by desulfuration & oxidation through
1)  P450 isoenzymes, 
2) Mono-oxygenase which has flavin  , 
3)  N & S oxidation.
         The inhibiting oxons are deactivated by hydrolases
 a) Carboxylases &
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b) A-esterases (paraoxonase). 
Enzymes  such  as  paraoxonase  1  (PON1)  contribute  to  endogenous
hydrolysis  of  organophosphates,  prodrugs  &  lipids.  All  except  few
organophosphorous  pesticides  are  catabolised  rapidly  and  excreted  through
kidney. Only few are found in serum after two days following intoxication.(27).
Elimination
Excretion commonly occurs through kidney and a few extent in faeces &
through  lung  during  expiration.  Few  organophosphorous  compounds  like
dichlorvos  can be excreted within few hours because it is not fat soluble and
not  stored  in  fatty  tissues.   In  contrast  inhibing  oxon  of  chlorpyrifos  or
dementon-S-methyl  can be present in fatty tissues as it is stored heavily in fat. 
TOXICOLOGY
OP  compounds  has  various  chemicals  which  vary  in  physical  and
biochemical and metabolic properties ,because of this nature the toxicity profile
also varies  specifically  with each agent.   The lethal  effects  also depends on
exposure route, amount consumed, contact time with the substance & lastly on
individual  patient  status.  Estimation  of  relative  human  toxicity  is  especially
based upon the measured  oral  LD50  in rats. The World health organization
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revealed  the rating of toxicity in 2002 and classified pesticides as extremely
hazardous
 (Ia) (liquid state: LD50 < 20 mg/kg); high 
 (Ib) (20–200 mg/kg); moderate
(2) (200–2000 mg/kg); and slightly potent
 (3)When it exceeds >2000 mg/kg it is highly hazardous agents are labelled as
Poison or  Toxic on commercial  preperations.  The World health organization
classification  is  different  from  that  proposed  by   EPA,  which  classifies
organophosphorous   compounds  as  high  toxicity  (rat  LD50  <  50  mg/kg),
intermediate or moderate toxicity (LD50, 50–1000 mg/kg) and low toxicity (LD
50 > 1000mg/kg)28 .
Thus, lethal doses for humans can vary from a few mg for highly toxic
agents like TEPP , to 50 g for the low-toxicity agents like malathion. Even one
milligram of nerve agent such as  soman /sarin  is hazardous to people following
inhalation . 
For  volatile /aerosolized/nerve agents ,attribution of  toxicity is  by a
concentration time (Ct) variable that is a better measure of inhalational exposure
For  nerve  gas   agents,  the  lethal  Ct  50  varies   from  10  to  400
milligram/minute/m3.
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 CLINICAL MANIFESTATIONS OF ORGANOPHOSPHORUS
POISONING:
Muscaranic features 
DUMBELS SLUDGE
D-DIARRHOEA,DIAPHORESIS S-SALIVATION
U-URINARY INCONTINENCE L-LACRIMATION
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M-MIOSIS U-URINARY INCONTINENCE
B-BRONCHORRHOEA
BRONCHOSPASM
BRADYCARDIA
BLURRING OF VISION
D-DIARRHOEA
E-EMESIS G-GI  DISTRESS
L-LACRIMATION E-EMESIS
S-SALIVATION
NICOTINIC FEATURES- CNS MANIFESTATIONS
(LESS WITH CARBAMATES)
MUSCLE
FASCICULATIONS(STRIATED)
UNCONCIOUSNESS
MUSCLE WEAKNESS CONFUSION,FATIGUE
PARALYSIS TOXIC PSYCHOSIS,SEIZURE
HYPERTENSION RESPIRATORY DEPRESSION
TACHYCARDIA ATAXIA,DYSARTHRIA
MYDRIASIS (RARE) EXTRA PYRAMIDAL FEATURES
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  Acute Intoxication
 Clinical features of acute poisoning manifest by muscaranic and nicotinic
signs & symptoms but for extremely low lipid soluble agents manifest by signs
referable to   central  nervous system. Within minutes following exposure to
vaporizing agents the clinical manifestation occurs.
On the other hand, the symptomatology is delayed after oral or cutaneous
absorption.  Depends upon the chemical nature of substances the duration of
symptoms varies depends on  fat solubility, whether it is an active compound or
has to be activated to oxon , the stable nature  of the orgaophosphorous-AChE
bond, and whether aging  of enzyme occurs.
   Exposure  to  vapours  &  aerosols  or  after  their  inhalation,  eye  &
respiratory  manifestations  happens  initially.  Ocular  manifestations  include
papillary  constriction,  decreased  visual  acuity,  ocular  ache,  congested
conjunctiva & ciliary muscle spasm. Some times when the patient presents with
hypotension  in  organophosphorous  poisoning  pupillary  constriction  will  not
there, because of reflex sympathetic activation. 
 Respiratory manifestations
Upper  respiratory  tract  manifestations  include  respiratory  effects  to
rhinorrhea and hyperaemia. In lower respiratory tract due to bronchorrhoea and
there may be wheeze and chest tightness
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  Gastrointestinal symptoms
May present early with nausea, anorexia, vomiting, cramps in abdomen &
loose stools. 
  Skin &others
         When adsorption happens through skin can lead to local sweating &
muscle fasciculation’s are the most common early symptoms. Severe poisoning
is  manifested  by  excessive  salivation,  involuntary  urination  &  defecation
lacrimation, sweating, erection of penis, bradycardia, and hypotension. 
Neuromuscular
Nicotinic  actions  at    skeletal  neuromuscular  junction  manifest  with
fatigue, involuntary twitching & fasciculation’s followed by muscle weakness
& muscle palsy. When respiratory muscle palsy happens leads to respiratory
failure which may need intubation and mechanical ventilation. Knockout mice
lacking AChE can survive under highly supportive conditions and with a special
diet, but they exhibit continuous tremors and are stunted in growth (29) .
Mice that selectively lack AChE in skeletal muscle but have normal or
near normal expression in brain & other tissues innervated by the ANS grow
normally & reproduce, but have continuous tremors (30) . These studies show that
cholinergic  systems  can  partially  adapt  to  chronically  diminish  hydrolytic
capacity for AChE.
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Central nervous system
  The broad spectrum of effects of acute AChE inhibition on the CNS includes
confusion,  ataxia,  and  slurred  speech,  loss  of  reflexes,  Cheyne  -  Stokes
respiration,  generalized  convulsions,  coma,  and  central  respiratory  paralysis.
Actions  on  the  vasomotor  and  other  cardiovascular  centers  in  the  medulla
oblongata lead to hypotension.
MORTALITY
  Mortality  following  single  acute  intoxication  may  range  from   <  5
minutes to around a day, depends on the dose, agent ,route & other factors.
 Leading cause of mortality is respiratory failure often with cardiovascular
compromise. Peripheral  nicotinic and muscaranic  as well as CNS effects all
can  lead  to  respiratory  compromise;  features  are   bronchoconstriction,
laryngospasm, abundant salivary & tracheobronchial and  secretions, reduced 
Voluntary control  over intercostal & diaphragmatic muscles, and respiratory
depression at CNS. Hypotension and arrhythmias can result of severe toxicity,
and due to hypoxemia and mostly are reversed by mechanical ventilation.
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 INTERMEDIATE SYNDROME
 Intermediary syndrome was first documented by  Senanayake  in 1987. It
is characterised by predominant weakness in flexors of neck, proximal muscles
& respiratory  muscles  ,he  also  called  this  syndrome  as  type  II  paralysis  31
Intermediary syndrome can develop 1-3 days following cholinergic crisis ,then
it  persists  for  many  days  up  to  few  weeks  (32).  There  are  opposite  views
regarding  the  presence  of   persistent  low  levels  of  Ach(due  to  insufficient
treatment with oxime) at myoneural junction  and intermediary syndrome(33)  .
   Absence of muscaranic stimulation with  reduced cholinesterase activity
(continuous  antagonism  by  acetylcholinesterase)  is  the  specific   feature
pertained  to  this  syndrome  ,furthermore  except  supportive  care  there  is  no
specific treatment options for this syndrome.(34) 
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       Nerve  Conduction  Studies  performed   throughout  the   intermediary
syndrome  phase  shows  have  shown  sequential  decline  in  in  neuromuscular
impulses with  repeated  stimulation at low rates ,gives the constant result of
presynaptic  & postsynaptic impulse diminution  at  neuro muscular junction
with desensitization (35)  There is no specific etiology at this point , Sri Lankan
pralidoxime study throws some light to the etiology but not specific to be taken
away  Few  people  suggests  giving  extra  amount  of  oximes  will  help  in
recovery ,but studies yet to come to support this.
DELAYED  POLYNEUROPATHY  (organophosphate-induced  delayed
neuropathy or polyneuropathy)
   Neuropathy target esterase is abundant in schwan cells which lines the
axons.  Organophosphorous  induced  neuropathy  is  occurs  when  few
organophosphorous  compounds  blocks  these  enzymes  along  with
acetylcholinesterase. 
 It  is  specially  associated  with  phosphates,  phosphoramidates,  and
phosphonates  types  of  OPCs  by  inhibiting  both  acetylcholinesterase  and
neuropathy  target  esterase  (NTE).  During  aging  which  causes  detriment  in
myelin sheath a dying  back  axonopathy . 
When aged, causes loss of the myelin which will not respond to treatment
with atropine /pralidoxime (36) .This causes demyelination which is symmetrical
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and the patient presents history of  cramping pain, paresthesias,tingling ,pain &
distal extremity weakness. 
 It  takes  around  three  to  six  weeks  for  the  development  of  these
neurological symptoms following the exposure of toxin and it is progressive in
nature for several weeks to months(37).
 The diagnosis of neuropathy can be supported by measuring lymphocyte
neuropathy  target  esterase  (NTE)assay.  Decrease  in   of  lymphocyte  NTE
corresponds  with  the   development  of   OP-induced   delayed
neuropathy(OPIDN)(38) . 
No target therapy is available for OPIND ,it is only supportive treatment.
For mild cases resolution of neurological symptoms can happen over the span of
6 months to a year. But for patients who presents with severe OPIND, have
chronic persistent neurological deficits (39) .
   CHRONIC NEUROPSYCHIATRIC SEQUELAE
 There  are  few other  neurological  &  neuropsychiatric  sequlae  may  be
pertained to organophosphorous  poisoning .Immediately they may present with
acute  encephalopathy.  Patients  may  develop  severe  encephalopathy.
Chronically they can present  with  fatigue ,short-term memory loss,  fatigue,
confusion, psychosis ,depression, extra pyramidal/ Parkinsonism features (40) 
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DIAGNOSIS
  Organophosphorous poisoning diagnosis is supported by specific clinical
findings, like miosis is a strong predictor and history of exposure to a known
OP compound.  Measurement of  RBC /serum cholinesterase  level supports the
diagnosis . 
Electrodiagnostic studies are helpful to confirm it .When red blood cell
cholinesterase  level  drops  to  less  than  three  fourth  the  symptoms  of  OPC
intoxication will manifest, when the intoxication is severe the levels will be  <
10 percent. 
 But few studies did not support the positive association with symptom
severity and patients outcome (41).
  laboratory findings:
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 Usual  lab  studies  don’t  give  us  any  clue  usually  but  there  are  few
exceptions.  Occasionally  there  will  be hypokalemia and several  case studies
indicates that non ketotic hyperglycemia and glycosuria can happen.
 In Hayes’s study leucocytosis,  with or  without  a  left   shift,   was  a
common  observation  (42) .Due  to  parasympathetic  activation  and  increased
secretions  which  causes  pancreatic  injury   ,there  may  be  increase  in  serum
amylase levels. 
Electrocardiography  will  give  us  a  various   aberrations   in  acute
intoxication such as , sinus tachycardia, sinus  bradycardia,  AV  blocks, ST -T
changes &  Q-T  prolongation  and  rarely  various pattern of  arrhythmias  (43).
Laboratory findings significance
Neutrophilic leucocytosis  46%
hyperglycemia 23%
proteinuria 19%
glycosuria 14%
hyperamylasemia 14%
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EMG a)Decrement-increment  response  to
high frequency(30-50)RNS
b)Decrement response to high rate RNS
(30 -50 Hz)
Acidosis Poor prognosis
 Serum /rbc cholinesterase levels:
 Laboratory confirmation  of poisoning is documented  by  reduced
Serum / RBC   acetylcholinesterase levels. Out of these two enzymes serum
acetylcholinesterase activity has got   high inter-individual variations, so mild
poisoning cannot be established without successive decline in   cholinesterase
levels . RBC acetylcholinesterase is bound to the membrane and is harmonized
with  haemoglobin  in  the  RBC,  so  it  will  not  show  variations  between
individuals. 
Because  RBC  acetylcholinesterase  is  found   in  membrane  of   RBC
without reactivation of enzyme by oximes ,the levels will be diminished till the
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RBC’s die and new erythrocytes develops, so that is up to two to three months
the levels of RBC acetylcholinesterase activity is diminished(45).
     Regeneration of neuromuscular junction acetylcholinesterase  is rapid as
compared  to    RBC  acetylcholinesterase.  Butyrylcholinesterase  comes  to
baseline in two to four weeks since its an acute-phase reactant. In around  3% of
general  population there is baseline depression of butyrylcholinesterase activity
level due to genetic variations. Other conditions in which  butyrylcholinesterase
activity is decreased are pregnancy,hypoalbulinemia ,drugs ,congestive cardiac
failure  leading  to  secondary  hepatic  injury,parenchymal  liver  disease  and
metastatic cancers.
RBC cholinesterase Plasma cholinesterase
Advantage Better  reflection  of
synaptic inhibition
Easier to assay,declines faster
site CNS grey 
matter,RBC,
Motor end plate
CNS white 
matter,plasma,Liver,Pancreas,Heart
Regeneration 1% of day (25-30) in first 7 to 10 days
Normalization 35 to 49 days 28 to 42  days
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Use Unsuspected prior 
exposure with 
elevated plasma 
cholinesterase
Acute exposure
False
depression
Pernicious anaemia,
Haemoglobinopathies,
Anti malarial 
treatment,
Oxalate blood tubes
Cirrhosis,
Malnutrition,succinylcholine,codeine
Morphine,pregnancy
Genetic deficiency
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 Peradeniya organophosphorous poisoning (POP) scale:
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The  Peradeniya  Organophosphorous  Poisoning  (POP)  Scale is a scoring
system introduced by N Senanayake, H  J  de  Silva  and  L  Karalliedde  in
1993(46).   Usual   clinical   features   of   OPC intoxication   are   choosen  as
variables  and everyone  is  assessed  on  a  three-points score which varies from
0 to 2 (Table 4). A  score  of
1 to  3 is  considered  as  mild  poisoning,
2   4  to  7  as  moderate poisoning and 
8 to  11 as severe poisoning.
 MANAGEMENT
 Initial management:
 Airway   management  is  the  mainstay  in  managing   OP-  intoxicated
patient  .   Rapid atropinisation and oxygen are  the initial  mode of  treatment
when patients clinically presents with crepitations and excessive bronchial or
oral secretions ,hypoxia or cyanosis. Eddleston from Srilanka demonstrated in a
cohort  study  that  there  is  no  increased  cardiotoxicity  with   early  and  rapid
atropinisation in a cohort study (47).
 The antidote should be given till pulmonary oedema subsides and oral
and bronchial secretions have dried.
  If respiratory compromise occurs during rapid  atropinization, it should
be  should be handled by securing the airway  with intubation with or without
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mechanical  ventilation,  and frequent  suctioning of  oral  cavity and airway as
well.  
   In  (RSI)  that  is  rapid  sequence  intubation  depolarizing  blockers  such  as
succinylcholine though not contraindicated should be used with great caution
since it is metabolism depends on butyrylcholinesterase. So when this is enzyme
is inhibited it can lead to prolonged paralysis. 
 GI loss : 
  Organophosphorous  compound  intoxication  leads  to  nitric  oxide
mediated vasodilatation of GI vessels and leads to moderate to severe  GI fluid
loss.51  For this isotonic saline should be infused rapidly  by IV. For the patient
to become euvolemic  around 2 L or more fluid is needed. When hemodynamic
compromise is  there  even  with  atropine and IV fluids   one should  go with
vasopressors .  Among the vasopressors , phenylephrine is chosen because it
acts  directly  on  α  receptors  in  adrenergic  system ,since  intoxicated  persons
have  a  relatively  normal  inotropic  state  and  a  reduced  systemic  vascular
resistance(48).
  Seizure 
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  Seizure should b controlled rapidly with drugs acting through  GABA
like lorazepam ,midazolam or diazepam. Aggressive benzodiazepine use during
seizure  will  increase  overall  survival  by  reducing  cardiac  and  CNS
complications . Widely accepted treatment regimen for adults to control seizure
activity  is 5 to 10 mg of IM midazolam or 10 mg IV diazepam,  for paediatric
patients dosing is    0.1–0.2 mg/kg  of IV diazepam  or 0.1–0.3 mg /  kg of
midazolam  IM with dose titration as required.
 Decontamination:
Decontamination  is the next priority after initial clinical stabilization of
patient.  In  liquid contaminations when the clothing’s are soiled patient will
have continuing  cutaneous adsorption of OPCs. Thus, as quick as possible, one
should  undress the intoxicated person then  skin should be washed thoroughly
with water  and alkaline-soap solution.  Life saving resuscitation and antidote
administration  should  not  be  delayed  because  of  the  above  measures.
Undressing eliminates around 85% to 90% of a contaminated OP compounds(49).
  During decontamination care giver should self protect himself or herself
with adequate personal protecting equipment especially in OP and nerve agent
poisonings  .  at  the  site  initial  decontamination  should  be  done  by  trained
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persons who are handling hazardous materials by protection level of A or B.
After transfer of patient to hospital setup, hospital  staffs should be equipped
with   minimum of  Level C protection with covering shoes , nitrile , butyl  or
neoprenenitrile gloves &  facial splash protection and  impermeable gowns.
     Gastric  lavage   following  ester  OPC  poisoning   is  debatable.  Since
organophosphorous esters are strongly emetic, intoxicated persons will vomit
before seeking health care.  For patients presenting  with in an hour of ingestion
we can go with  empirical gastric decontamination  of an ingested material. But
it  is  not  supported  by   RCTs  .  Activated  charcoal  binds  to  few
organophosphorous  insecticides  ,so  activated  charcoal   through oral  route  is
usually recommended in intoxicated patients through orally. 
Aspiration risk 
    Most of the organophosphorous  compounds  are dissolved in hydrocarbon
solvents.  This  hydrocarbon  compounds  have  a  tendency  to  cause  severe
chemical pneumonitis  when aspiration into airway occurs. So the advantage of
nasogastric   aspiration  should  be  balanced  against  the  risk  of  aspiration
pneumonitis (50).
  Anticholinergic agents:
  Generous use of atropine (for muscaranic symptoms) and oximes to regenerate
acetylcholinesterase   is  the  mainstay  in  treatment  of  of   OP  poisoning  (51).
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Atropine inhibits post synaptic binding of acetylcholine(muscaranic receptors),
it crosses blood brain barrier since its a tertiary amine and acts also on central
muscaranic receptors. 
Atropinization 
   Atropine takes control  over  muscaranic symptoms like  bronchorrhoea
and   at  times   bradyarrhythmias  and  clinical   hypotension.  The  dosing  of
atropine is not constant.
And  the  dosing  regime  followed   by  Eddleston  and  colleagues  from
srilanka  recommends  rapid  and  intensifying  doses  of  cholinergic  antagonist
(atropinisation) ,followed by maintenance atropine infusion is associated with
more  success  in  protecting  the  airway  from  secretions  and  controls  other
muscaranic symptoms  (52).
By this regime, patients with muscaranic symptoms are given 1 to 2 mg
IV atropine at the beginning, and doubling doses at every five minutes interval
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as required. This regime will rapidly give forth a accumulative dose of 25 mg
by 20 min and 75 mg by 25 min. 
 Patients  with  severe  toxicity  may  need   75  to  100  mg  of  atropine.
Adequate dose  of atropinization is  assessed  by disappearance  of  secretions
from the bronchial  tree (clinically- disappearance of crackles )heart rate  >80
beats/min,  dry  skin,  and  a  mean  blood   pressure  >  60  mm  Hg  or  clinical
indicators organ reperfusion. Dilatation of  Pupil is a late sign of atropinization
it lags behind recovery of crepitations and bradycardia (approximately 30 min).
But non constricted pupil should be the goal.
Oximes in treatment:
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 They inhibit OPC and activates the inhibited enzyme . two groups of
oximes that  are clinically essential  are  1) bispyridinium  2)monopyridinium
oximes . in treatment pralidoxime which is a monopyridinium oxime is applied
widely.  Obidoxime (LuH-6,  Toxogonin)  trimedoxime (TMB-4)  and asoxime
(HI-6),while  the most important  bispyridinium  oximes and their structure is as
below. But still there is no clearcut evidence to use which oxime for clinical
effectiveness. 
        In 1950s Wilson and colleagues discovered PAM-2,soon it  was used
clinically in parathion intoxicated patients. Among the various oximes described
only  pralidoxime is  used  widely.  Its  structure  includes  four  salts  –mesilate,
chloride, iodide and metisulfate . 
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Extensively used one are chloride and  iodide salts , but in France , UK
and Belgium mesilate & metisulfate are used commonly . Among chloride  &
iodide,  chloride  has  advantage by having  low  molecular  weight.  (Chloridr-
173,iodide-264  )because  of  low  molecular  weight  it  gives  more  active
compounds approximately one to five times than iodide per gram of compound.
Also evidence suggests that thyrotoxicity is more when iodide-pralidoxime is
used  and exposure is prolonged(53).
 The effectiveness of pralidoxime was studied in Tamilnadu, Vellore  in
1990s.the results  were inconclusive. It concludes there is harm in infusing low
dose  pralidoxime.  the  ineffectiveness  could  be  explained  by  1)trial  related
factors like bias in allocation and suboptimal dose. Inspite of its (pralidoxime)
benefits  with  parathion intoxication ,its role has been questioned especially by
asian  doctors  .  Of  importance,  in  1990s   two  clinical  trials  in  Tamilnadu
,concluded  that  pralidoxime in low dose infusion can be dangerous.
 
Absence of advantage may be due to
1)  Trial design (insufficient dose, or allocation bias )
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2)Toxin related that is due to
            a) various types of poisons and
            b)varied amount of consumption
            c)high serum level of toxin which re-inhibits acetylcholinesterase that
are reactivated by oximes or 
3 )  patient related factors like
             a) delay in seeking treatment
              b)if hypoxic brain injury or aspiration pneumonia like complications
develop the effectiveness of oximes will be less ,they are common with fast
acting pesticides like dichlorvos and parathion.The conclusion of observational
studies  with  pralidoxime  and  obidoxime  to  reverse  inhibition  of
acetylcholinesterase is depends on the type of pesticide ingested(54) .  Oximes are
recommended by WHO for all symptomatic patients who requires atropine (55).
Initially a loading dose is given (pralidoxime chloride or obidoxime)  to attain
therapeutic  concentration  followed  by  continuous  infusion.   When  oxime
loading dose is given as bolus as rapidly they can cause vomiting which can
lead to aspiration ,also can cause diastolic hypertension and tachycardia.(56).
In  OPC  intoxication    Pralidoxime  should  be  given  as  500  mg/hr
continuous infusion till  patients clinical pattern improves or  30 mg / kg IV
bolus for  4–6 h or 8–10 mg /kg / hr IV  till clinical improvement & recovery .
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    PAM dose for  children are 25 mg/kg IV for  15 to 30 min followed by
continuous  IV  infusion of 10 to 20 mg / kg / hour In paediatric group.PAM can
be  infused till clinical recovery or upto  18 hours based on clinical situation(57).
 Obidoxime:
 Obidoxime was given to  volunteers by  IM .The dose of   5 mg / kg
brings  a serum level  of >4 mg/L  when 5mg /kg is given ( 5min  after
injection to 3 hr). Adverse reactions includes  sore throat  headache ,generalized
weakness,  nausea, pallor,  burning  sensation,   and  numbness of  the  face.
After   higher   doses  of   grams  per  day  in  severely   poisoned   individuals,
increased  serum  transaminases,  jaundice  and  cholestasis  like  hepatotoxic
features observed occasionally(58). 
  Dose  of   obidoxime   in   adults  is  250mg   slow  IV ,  after  that
continuous  IV infusion of  750 mg / day, to  attain a serum level  of 10–20
µmol / L , 0.4 mg/kg /hr should be given. Obidoxime can be given IM  when IV
access is impossible. Paediatric  dose of obidoxime is 3 to 6 mg / kg slow IV
over  5min(57).
 
Asoxime  (HI-6): 
    It  can  be  given as  500  mg or  250 mg IM.The plasma concentration
reaches >4 mg / L after five minutes of IM route. When 500 mg was  given the
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plasma concentration was maintained upto 200 minutes, when 250 mg injected
the concentration was maintained upto 125 minutes. It was given as 500 mg 6th
hourly  IM with atropine. Diazepam was also concurrently given.
 Continuation of oxime therapy should be upto 2-7 days depending upon
clinical status.
   22 healthy human volunteers was given HI-6  500 mg by orally, there
was  no  adverse  reactions  .following  nerve  agents  intoxications  HI-6
(bispyridinium oxime)works  well  as  a  treatment  modality.  The drawback of
HI-6  as compared  to
other   oximes   is  its  unstable  nature   in   aqueous   formulations.   In  OPC
compound poisoning HI-6  was  an  successful  antagonist  in  combination
with  atropine  & diazepam  in therapy(58).
 Oximes are ineffective when complications occur after OPC especially with
rapid acting agents like dichlorvos and parathion (59).
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Challenges commonly encountered in treatment of OP Compounds   
 1)  Inadequacy of  Forensic labs in Government  setup
 2)  Lack of toxicology Information Centres.  
3) Lack of  education  regarding of  use of  pesticides.
4) Inadequacy of health care professionals  in studies regarding poison 
4) Unavailability of newer antidotes.
5) Easy availability of OP compounds (especially pesticides) in the market.  6) 
Indeterminate quantitative estimation in patients. 
7) Increased rate of  respiratory failure
8) Increasing incidence of  diaphragmatic palsy. 
9) Increased  exposure and or consumption  leads to  development of 
hemorrhagic pancreatitis.
10) Increased use of  pesticides raises  health hazard in people  leading to 
reduction in  GDP.
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 Prevention of OP Poisoning:
1. It is better to prevent rather than to treat the patient because of  toxicity &
treatments risk. 
2. Before using pesticides in home make sure that windows and doors are open
to allow necessary ventilation.
3.  When  pesticides  are  labelled  to  be  used  outdoors  don’t  use  it  in  home
environment.
4. Follow  the instructions  & warnings  printed in  pesticides  label’s always.
5. Always use  products which can be used instantly ,instead of products that
require mixing.
6. Don’t keep any food material in and around the area of application or keep it
covered adequately.  
7. Before consuming food materials wash them thoroughly.
8. Dispose the insecticide containers carefully. Don’t use them for any other
purpose .Even if it is washed thoroughly there will be some insecticide remains
in it.
9. Avoid transferring pesticides to other containers, can be mistakenly handled
by children.
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10. While using insecticide use gloves and other protective clothes.
11. Wash hands after handling pesticides.
12. Ensure regular washing of children’s hands throughout the day.
13. Keep the as not reachable to children
14. Educate the children regarding   poisons and their ill effects.
15. Dont put pesticides in toilet / drainage system (68).
AIMS AND OBJECTIVES
1.  To  study  the  clinical  profile  of  myocardial  involvement  in  various
organophosphorous compound poisoning.
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2. To study prevalence and predictors of outcomes of myocardial injury with
Creatine phosphokinase MB as biomarkers in organophosphorous poisoning.
3. To correlate the myocardial injury with the clinical severity and outcome in
organophosphorous poisoning. 
MATERIALS AND METHODS
PLACE OF STUDY:
Department of general medicine, Intensive medical care ward (IMCW),General
Medical Wards, stanely medical college and hospital, chennai.
DURATION:
February 2014 to September 2014
STUDY DESIGN
Prospective and observational study
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SOURCE OF DATA:
Patients with history of organophosphorous poison consumption who fulfil the
inclusion  and  exclusion  criteria,  getting  admitted  at  stanley  medical  college
chennai, during the period of February 2014 to September 2014
SAMPLE SIZE :                
 60 patients
INCLUSION CRITERIA: 
1. All symptomatic patients having ingested organophosphorous compound
with moderate and severe organophosphorous poisoning.
EXCLUSION CRITERIA:
1. Patients who have ingested other substance in addition to op will also be
excluded.
2. patients who are known to have pre existing heart disease like rheumatic
heart disease,  ischemic heart disease etc. 
3. Patients who are hypertensive’s.
4. Patients who are chronic alcoholics.
5. Patients with chronic kidney disease.
6. Patients who are below the age of 12 years.
7. Patients aged more than 70 years.
8. Patients  who are known to have muscular, neuromuscular disease.
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                              METHODOLOGY
Patients admitted with ingestion of organophosphorous compound to the
Intensive medical care unit (IMCW) from February 2014 to September 2014
are  included  in  the  study.  Patients  will  be  subjected  to  symptom analysis,
clinical examination, laboratory investigations. The final analysis will be made
at the end of the study to achieve the fore mentioned goals.
  Data will be collected using a pretested proforma meeting the objectives
of  the  study.  Detailed  history,  physical  examination  and  necessary
investigations will be undertaken. The purpose of the study will be explained to
the patient and informed consent obtained.
 Using  non-invasive  methods  cardiac  injury  in  organophosphorous
poisoning who fulfil  the inclusion criteria  are  assessed and also  analyse the
cardiac enzyme levels with the outcome of the patient.
 Patients  are  classified  into  three  grades  using  “Peradeniya
organophosphorous poisoning scale”.
 Changes in ECG will be monitored and serum Creatine phosphokinase –
MB, serum cholinesterase levels will be measured at admission and repeated on
third day and seventh day or at discharge. If the stay is more than seven days
they are tested on alternate days till discharge, and taken for analysis. 
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 The  course  of  acute  cardiac  injury  and  enzyme  levels  in
organophosphorous poisoning and its effect on the prognosis will be assessed. 
CPK  –MB  level  of  >40  U/L  is  considered  to  have  a  significant
association with cardiac injury.
The  analysis  of  the  data  will  be  done  using  appropriate  statistical
methods.
Clinical severity is assessed by Peradeniya scoring system and it is used
to compare with other parameters of the study.
PERADENIYA SCORE
This scale includes patients who attended hospital within 24 hrs of consumption
of poisoning without any medical intervention .This criteria is based on patients
at the time of admission and classified as mild moderate and severe poisoning.
As per our goals blood samples are sent. Full recovery and death are considered
as end points.
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RESULTS  AND  DISCUSSION 
Descriptive  statistics  was  done  for  all  data  and  suitable  statistical  tests  of
comparison were done. Continuous variables were analysed with the Unpaired t
test/Anova and categorical variables were analysed with the Chi-Square Test
and Fisher Exact Test. Statistical significance was taken as P < 0.05. The data
was  analysed  using  EpiInfo  software  (7.1.0.6  version;  Center  for  disease
control, USA) and Microsoft Excel 2010.
Sample Size Calculation
Sample  size  was  determined  on  the  basis  of  a  pilot  study  in  which  the
prevalence  of  death  among  organophosphorous  poisoning  patients  was
measured at 4%.  We calculated a minimum sample size of 59 patients was
required, assuming a type 1 error (two-tailed) of 0.05 and a margin of error of
10%. Therefore, the final sample selected was n= 60.
n= t²    x    p(1-p)
 m²
Description:
n = required sample size
t = confidence level at 95% (standard value of 1.96)
p = estimated prevalence of malnutrition in the project area
m = margin of error at 10% (standard value of 0.05)
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n= (1.96)²    x    0.04(1-0865)
            (0.05)²
n= 3.8146    x    0.0384
 
           0.0025
= 59
= 60 in the study group
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Age in
Years
All % Male % Female %
≤ 15 0 0.00 0 0.00 0 0.00
16 to 30 35 58.33 29 64.44 6 40.00
31 to 45 19 31.67 12 26.67 7 46.67
46 to 60 5 8.33 3 6.67 2 13.33
≥ 60 1 1.67 1 2.22 0 0.00
Total 60 100 45 100 15 100
AGE
N 60
Mean 30.15
SD 11.01128
P value
One sample t test
0.1002
By  conventional  criteria  the  study  variable  age  is  considered  to  be  not
statistically significant since p > 0.05.
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Gender Distribution Number of Observations %
Male 45 75
Female 15 25
Total 60 100
P value
One sample z test for
proportions
1.0457
By conventional criteria the study variable gender is considered to be not
statistically significant since p > 0.05.
Since age and gender is not statistically significant, it means that there is
no difference between the groups. In other words the groups contain subjects
with the same basic demographic characteristics.
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ORGANOPHOSPHOROUS POISON
Chlorpyriphos
Dimethoate
Methyl parathion
quniolphos
phorate
unknown
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Organophosphorous Poison
Number of Subjects
Organophosphorous Poison N %
Chlorpyriphos 18 30.00
Dimethoate 9 15.00
Methyl parathion 10 16.67
quniolphos 3 5.00
phorate 6 10.00
unknown 14 23.33
Total 60 100
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POISON SEVERITY
Mild
Moderate
Severe
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Poison Severity
Number of Subjects
Poison Severity N %
Mild 20 33.33
Moderate 29 48.33
Severe 11 18.33
Total 60 100
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CLINICAL SYMPTOMS
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Absent 36 60.00 41 68.33 39 65.00 52 86.67
Present 24 40.00 19 31.67 21 35.00 8 13.33
Total 60 100 60 100 60 100 60 100
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CPK‐MB Levels
 DAY 1 CPK‐MB
 DAY 3 CPK‐MB
 DAY 7 CPK‐MB
Number of Subjects
CPK‐MB DAY 1
CPK‐MB
% DAY 3
CPK‐MB
% DAY 7
CPK‐MB
%
≤ 20 4 6.666667 3 5.263158 5 9.090909
21 to 30 25 41.66667 19 33.33333 23 41.81818
31 to 40 23 38.33333 21 36.84211 18 32.72727
41 to 50 8 13.33333 14 24.5614 9 16.36364
Total 60 100 57 100 55 100
CPK‐MB DAY 1 CPK‐MB DAY 3 CPK‐MB DAY 7 CPK‐MB
N 60 57 55
Mean 30.93333 32.21053 30.38182
SD 7.848284 8.741385 9.288294
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Total 60 100 57 100 54 100
Serum
Cholinesterase
DAY 1  S.
CHOLINESTERASE
DAY 3  S.
CHOLINESTERASE
DAY 7  S.
CHOLINESTERASE
N 60 57 54
Mean 2176.95 2520.772 3438.241
SD 921.0435 1063.572 4028.406
Mechanical Ventilation
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Mechanical Ventilation Number of
Observations
%
Mechanical Ventilation ‐ 45 75
Mechanical Ventilation + 15 25
Total 60 100
ICU Stay
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ICU Stay N %
≤ 3 Days 40 70.18
4 to 7 days 11 19.30
> 7 days 6 10.53
Total 57 100
ICU Stay
N 57
Mean 3.245614
SD 2.230316
Treatment Outcome 
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Outcome N %
Alive 52 86.67
Dead 8 13.33
Total 60 100
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DAY 3 CPK‐MB POSITIVITY
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DAY 3 CPK‐
MB
Positivity
Mechanical
Ventilation ‐
% Mechanical
Ventilation +
%
Negative 42 93.33 1 8.33
Positive 3 6.67 11 91.67
Total 45 100 12 100
Chi square
statistic
36.9 
Degrees of
freedom
1
P value
Chi squared
test
0.000
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By conventional criteria the association between  DAY 3 CPK-MB Positivity
and respiratory depression is considered to be statistically significant since p <
0.05.
Statistical Significance
This indicates that there is a true difference among the study groups and the 
difference is significant. 
In simple terms,  while studying myocardial injury in organophosphorous 
compound poisoning, the incidence DAY 3 CPK-MB Positivity 3 in patients 
without respiratory depression and 11 in patients with respiratory depression 
with a p-value of 0.000 according to Chi-Squared test.
Clinical Significance
The incidence of DAY 3 CPK-MB Positivity among patients treated for 
myocardial injury in organophosphorous compound poisoning was 
meaningfully less(6.67%) in patients without respiratory depression  compared 
to patients with respiratory depression (91.67%). This difference is true and 
significant and has not occurred by chance.
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Conclusion 
We conclude that there is real advantage if the patient is classified based on
DAY  3  CPK-MB  Positivity,  which  in  turn  increases  the  risk  of  having
respiratory  depression.  This  also  proves  there  is  an  increasing  trend  of
respiratory depression with DAY 3 CPK-MB Positivity.
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ECG ST Change Positivity
Mechcanical Ventilation ‐
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ECG ST
Change
Positivity
Mechanical
Ventilation ‐
% Mechanical
Ventilation +
%
Negative 36 80.00 8 53.33
Positive 9 20.00 7 46.67
Total 45 100 15 100
Chi square
statistic
4.09 
Degrees of
freedom
1
P value
Chi
squared
test
0.043
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By conventional criteria the association between ECG ST Change Positivity  and
respiratory depression is considered to be statistically significant since p < 0.05.
Statistical Significance
This indicates that there is a true difference among the study groups and the 
difference is significant. In simple terms,  while studying myocardial injury in 
organophosphorous compound poisoning, the incidence ECG ST Change 
Positivity 9 in patients without respiratory depression and 7 in patients with 
respiratory depression with a p-value of 0.043 according to Chi-Squared test.
Clinical Significance
The incidence ECG ST Change Positivity among patients treated for myocardial 
injury in organophosphorous compound poisoning was meaningfully less(20%) 
in patients without respiratory depression  compared to patients with respiratory
depression (46.67%). This difference is true and significant and has not 
occurred by chance.
Conclusion 
We conclude that there is real advantage if the patient is classified based on ECG
ST  Change  Positivity,  which  in  turn  increases  the  risk  of  having  respiratory
depression.  This  also  proves  there  is  an  increasing  trend  of  respiratory
depression with ECG ST Change Positivity.
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ECG QT PROLONGATION POSITIVITY
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ECG QT
Prolongation
Positivity
Mechanical
Ventilation ‐
% Mechanical
Ventilation +
%
Negative 40 88.89 9 60.00
Positive 5 11.11 6 40.00
Total 45 100 15 100
Chi square
statistic
6.27 
Degrees of
freedom
1
P value
Chi squared
test
0.012
By conventional criteria the association between ECG QT Prolongation Positivity
and respiratory depression is considered to be statistically significant 
since p < 0.05.
Statistical Significance
This indicates that there is a true difference among the study groups and the 
difference is significant. 
In simple terms, while studying myocardial injury in organophosphorous 
compound poisoning, the incidence ECG QT Prolongation Positivity 5 in patients
without respiratory depression and 6 in patients with respiratory depression 
with a p-value of 0.012 according to Chi-Squared test.
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Clinical Significance
The incidence ECG QT Prolongation Positivity among patients treated for 
myocardial injury in organophosphorous compound poisoning was 
meaningfully less(11.11%) in patients without respiratory depression  compared
to patients with respiratory depression (40.00%). This difference is true and 
significant and has not occurred by chance.
Conclusion 
We conclude that there is real advantage if the patient is classified based on ECG
QT Prolongation Positivity, which in turn increases the risk of having respiratory
depression.  This  also  proves  there  is  an  increasing  trend  of  respiratory
depression with ECG QT Prolongation Positivity.
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DAY 3 CPK-MB AND MORTALITY
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Mortality ‐ % Mortality + %
Negative 48 92.31 4 50.00
Positive 4 7.69 4 50.00
Total 52 100 8 100
Chi square
statistic
10.7 
Degrees of
freedom
1
P value
Chi squared
test
0.001
By conventional criteria the association between DAY 3 CPK‐MB Positivity and
mortality is considered to be statistically significant since p < 0.05.
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Statistical Significance
This indicates that there is a true difference among the study groups and the 
difference is significant. 
In simple terms, while studying myocardial injury in organophosphorous 
compound poisoning, the incidence DAY 3 CPK‐MB Positivity 4 in patients alive 
and 4 in patients dead with a p-value of 0.001 according to Chi-Squared test.
Clinical Significance
The incidence of DAY 3 CPK‐MB Positivity among patients treated for 
myocardial injury in organophosphorous compound poisoning was 
meaningfully less(7.69%) in patients alive compared to patients dead  (50%). 
This difference is true and significant and has not occurred by chance.
Conclusion 
We conclude that there is real advantage if the patient is classified based on DAY
3 CPK‐MB Positivity, which in turn increases the risk of death. This also proves
there is an increasing trend of mortality with DAY 3 CPK‐MB Positivity.
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ECG QT Prolongation and Mortality
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and Mortality
Mortality ‐ % Mortality + %
Negative 45 84.91 4 57.14
Positive 8 15.09 3 42.86
Total 53 100 7 100
Chi square
statistic
3.18 
Degrees of
freedom
1
P value
Chi squared test
0.074
By conventional criteria the association between ECG QT Prolongation Positivity
and mortality is considered to be not statistically significant since p > 0.05.
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DAY 3
CPK‐MB
Vs
Clinical
Severity
Mild % Moderate % Severe %
Negative 14 77.78 21 75.00 8 72.73
Positive 4 22.22 7 25.00 3 27.27
Total 18 100 28 100 11 100
Chi
square
statistic
0.99
Degrees
of
freedom
2
P value
Chi
squared
test
0.951
By conventional criteria the association between  DAY 3 CPK‐MB Positivity and
clinical severity is considered to be statistically not significant since p > 0.05.
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ECG QT PROLONGATION VS CLINICAL SEVERITY
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Mild % Moderate % Severe %
Negative 19 95.00 24 82.76 6 54.55
Positive 1 5.00 5 17.24 5 45.45
Total 20 100 29 100 11 100
Chi square
statistic
7.80 
Degrees of
freedom
2
P value
Chi squared
test
0.020
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By conventional  criteria  the  association between  ECG QT Prolongation  and
Clinical Severity is considered to be statistically significant since p < 0.05.
Statistical Significance
This indicates that there is a true difference among the study groups and the 
difference is significant. 
In simple terms, while studying myocardial injury in organophosphorous 
compound poisoning, the incidence ECG QT Prolongation Positivity5 in 
patients with mild clinical symptoms and 5 in patients with moderate clinical 
symptoms and 5 in patients with severe clinical symptoms with a p-value of 
0.020 according to Chi-Squared test.
Clinical Significance
The incidence of ECG QT Prolongation Positivity among patients treated for 
myocardial injury in organophosphorous compound poisoning was 
meaningfully less(5.00%) in patients mild clinical symptoms and 17.24%  in 
patients with moderate clinical symptoms and45.45% in patients with severe 
clinical symptoms/ This difference is true and significant and has not occurred 
by chance.
107
Conclusion 
We conclude that there is real advantage if the patient is classified based on
ECG QT Prolongation Positivity, which in turn increases the level of clinical
symptoms experienced. This also proves there is an increasing trend of clinical
severity with ECG QT Prolongation Positivity.
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CITATIONS 
1)Sadeesh et al  &
2)Balouch et al studied electrocardiographic changes in OP compound  
poisoning the results comparing the two studies are below
  Sadeesh et al  Balouch et al
  ST elevation  10.3 %  24 %
 Q-T prolgation  17.2 % 67 %
 Sinus tachycardia  12.6%  35 %
 Sinus bradycardia  14.9%  28 %
 3) Morteza Rahbar Taromsari et al  in 2012 studied cardiac injury in opc 
poisoning by ECG changes .In his study 49 had ECG changes.
  4) In  Rafigh Doost et al in Iran  studied  51 patients with OP poisoning, 33 
presented electrocardiographic changes.  64.71% of the patients had a prolonged
QTc interval . ST-T changes in 11 cases (29.7%), and conduction defects in two
cases (5.4%)( sinus bradycardia,sinus  tachycardia, atrioventricular arrhythmia, 
conduction disturbances, prolonged QTc interval, and non-specific changes in 
ST segment and T wave are studied )
5) Karki et al study  reported that sinus tachycardia occurred in 40.5% 
prolonged QTc interval in 14 cases (37.8%) and  of  OP compound poisoned 
patients 
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   6) Yurumez et al. reported that sinus tachycardia (in 31.8% cases) &
 (55.5%)  had a prolonged QTc interval.
 7)Chuang et al. determined that 97 (43.5%) patients had QTc prolongation, and
these patients had poor prognosis.
8) Jang et al. determined that 67 of 170 patients had QTc prolongation and in 
their  group, mortality rate, respiratory failure rate, and frequency of ventricular 
premature contractions were significantly higher than those of patients without 
QTc prolongation .
 9)Madhu Pankaj, Kavita Krishna reported acute Organophosphorus Poisoning 
Complicated by Acute Coronary Syndrome in a 30 year old man with fresh ST 
elevation and elevated CPK –MB levels ,and he was recovered well and 
discharged. This was published in JAPI 2014 July.
CONCLUSION OF THIS STUDY
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    We studied myocardial involvement in organophosphorous poisoning 
with cardiac enzyme levels and ECG changes, organophosphorous is a 
commonly encountered in Tamil Nadu.
¾ 60 patients were included in this study out of which 8 people were dead 
which gives a mortality of 13.33.
¾ This study showed there is no correlation of poison severity  with age or 
gender
¾ This study shows that clinically tachycardia is the most common that is 
40%, followed by hypertension 35%, bradycardia 31.67% and 
hypotension 13.33.
¾ According to changes in ECG the most common finding is sinus 
tachycardia (36.67%), followed by sinus bradycardia (30%),ST-T 
Changes (26.67%),QT prolongation( 18.33%),A-V Blocks (13.33 %) and
arrhythmias in 3.3% of patients.
¾ There is a positive correlation of respiratory depression with day 3 CPK-
MB level and ST-T changes and also with QT Prolongation.
¾ But it showed negative correlation of QT Prolongation with mortality.
¾  It also showed negative correlation with day 3 CPK-MB levels with 
clinical severity.
¾ QT Prolongation correlates positively with clinical severity
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இந்தமருத்துவஆய்வின்விவரங்கள்எனக்குவிளக்கப்பட்டது
.என்னுைடயசந்ேதகங்கைளக்ேகட்கவும்,அதற்கானதகுந்தவிளக்கங்கைளப்ெபறவும்வாய்ப்பளிக்கப்பட்டது .
நான்இவ்வாய்வில்தன்னிச்ைசயாகத்தான்பங்ேகற்கிேறன்
.எந்தகாரணத்தினாலும்
,எந்தகட்டத்திலும்
,எந்தசட்டசிக்கலும்இன்றிஇந்தஆய்விலிருந்துவிலகிக்ெகாள்ளலாம்என்றும்அறிந்துெகாண்ேடன் .
நான்ஆய்விலிருந்துவிலகிக்ெகாண்டாலும்ஆய்வாளர்என்னுைடயமருத்துவஅறிக்ைககைளப்பார்ப்பதற்ேகா
அல்லதுஉபேயாகிக்கேவாஎன்அனுமதிேதைவயில்ைல எனவும் 
அறிந்துெகாண்ேடன்.என்ைனப்பற்றியதகவல்கள்இரகசியமாகப்பாதுகாக்கப்படும்என்பைதயும்அறிேவன் .
இந்தஆய்வின்மூலம்கிைடக்கும்தகவல்கைளயும்ப¾ேசாதைனமுடிவுகைளயும்
.ஆய்வாளர்அவர்விருப்பத்திற்ேகற்பஎவ்விதமாகப்பயன்படுத்திக்ெகாள்ளவும்
,அதைனபிரசு¾க்கவும்முழுமனதுடன்சம்மதிக்கிேறன் .
இந்தஆய்வில்பங்குெகாள்ளஒப்புக்ெகாள்கிேறன்
.எனக்குெகாடுக்கப்பட்டஅறிவுைரகளின்படிநடந்துெகாள்வதுடன் , 
ஆய்வாளருக்குஉண்ைமயுடன்இருப்ேபன்என்றும்உறுதியளிக்கிேறன்
.என்உடல்நலம்பாதிக்கப்பட்டாேலாஅல்லதுவழக்கத்திற்குமாறானேநாய்க்குறிெதன்பட்டாேலாஉடேனஅைத
ைதெத¾விப்ேபன் என உறுதிகூறுகிேறன் .
இந்தஆய்வில்எனக்கு எவ்விதமான 
ப¾ேசாதைனகைளயும்,சிகிச்ைசகைளயும்ேமற்ெகாள்ளநான்முழுமனதுடன்சம்மதிக்கிேறன் .
இப்படிக்கு
ேநாயளியின்ைகெயாப்பம் ஆய்வாளர்ைகெயாப்பம்ெபயர் 
(மரு.கி¾தரன்.)

KEY TO MASTER CHART
ECG CHANGES
1-NORMAL ECG
2-SINUS TACHYCARDIA
3-SINUS BRADYCARDIA
4-ST-T CHANGES
5-Q-T PROLONGATION
6-A-V BLOCKS
7-ARRHYTHMIAS
M-MALE    F-FEMALE
P.SCORE-PERADINEYA SCORE
TACHY-TACHYCARDIA
BRADY-BRADYCARDIA
HT-HYPERTENSION
HYPO-HYPOTENSION
D1-FIRST  DAY
D3-THIRD DAY
D7-SEVENTH DAY
CPK-MB-CREATINE PHOSPHOKINASE –MB
S.ChE-SERUM CHOLINESTERASE
MEC.VEN-MECHANICAL VENTILATION 
S.NO AGE SEX COMPOUND P.SCORE GRADE TACHY BRADY HT HYPO ECG CHANGES
1 20 M
Chlorpyripho
s 3 MILD      +      ‐     ‐ 2
2 22 M Dimethoate 8 SEVERE       ‐      +     + 4
3 23 M
Methyl 
parathion 5 MODERATE     + 2
4 17 M quniolphos 4 MODERATE  + 2
5 19 M
Methyl 
parathion 7 MODERATE  +  + 3
6 20 m
Chlorpyripho
s 8 SEVERE   +   + 3,4,5
7 47 F phorate 5 MODERATE  +  + 4
8 45 M Dimethoate 5 MODERATE   + 4
9 26 M quniolphos 2 MILD 1
10 18 M
Methyl 
parathion 4 MODERATE  + 2
11 25 M
Chlorpyripho
s 1 MILD  1
12 17 M unknown 4 MODERATE  + 1
13 65 M
Methyl 
parathion 8 SEVERE  +  + 3
14 30 M phorate 4 MODERATE  + 2
15 16 M Dimethoate 4 MODERATE  + 1
16 42 M Dimethoate 1 MILD 1
17 32 M
Chlorpyripho
s 8 SEVERE  +  + 3,5,6
18 36 F
Chlorpyripho
s 0 MILD  1
19 52 F unknown 5 MODERATE   + 6
20 17 F
Methyl 
parathion 4 MODERATE  +  2,4
21 19 M
Chlorpyripho
s 2 MILD  1
22 27 F Dimethoate 4 MODERATE  + 2
23 40 F unknown 1 MILD  +  + 2
24 22 M unknown 4 MODERATE   +  + 3,4
25 32 M
Chlorpyripho
s 5 MODERATE    +  +  3,5
26 40 F unknown 0 MILD  +  2
27 48 M
Methyl 
parathion 5 MODERATE  +    + 2,4
28 27 M Dimethoate 3 MILD  +  + 2
29 26 F phorate 4 MODERATE  + 3,6
30 23 F unknown 6 MODERATE  + 3,5
31 32 F
Chlorpyripho
s 2 MILD  +  2
32 27 M
Chlorpyripho
s 9 SEVERE   ‐   + 3,4
33 24 M Dimethoate 0 MILD  + 2
34 20 F unknown 4 MODERATE   + 3
35 27 M unknown 3 MILD  +   2
36 45 M quniolphos 1 MILD  +  1
37 39 M phorate 5 MODERATE   +   + 3,5
38 37 M
Chlorpyripho
s 8 SEVERE   +   +  3,2,6
39 33 M
Chlorpyripho
s 9 SEVERE   +   + 3,4,5
S.NO AGE SEX COMPOUND P.SCORE GRADE TACHY BRADY HT HYPO ECG CHANGES
40 19 M Dimethoate 3 MILD  + 2
41 50 M unknown 4 MODERATE  +  + 2
42 26 M
Methyl 
parathion 8 SEVERE  +  +  7
43 25 M
Methyl 
parathion 5 MODERATE    +  4
44 19 M phorate 0 MILD  1
45 42 M
Chlorpyripho
s 4 MODERATE  +  2,6
46 40 F
Chlorpyripho
s 2 MILD   +  5
47 25 M
Chlorpyripho
s 8 SEVERE  + 3,4,5,6
48 20 M
Chlorpyripho
s 4 MODERATE  +   + 2,4
49 50 M unknown 4 MODERATE   +  + 3,5
50 23 M unknown 3 MILD  + 1
51 16 F
Methyl 
parathion 2 MILD  +  2
52 40 M
Methyl 
parathion 4 MODERATE    + 1
53 20 M Dimethoate 8 SEVERE   +  + 3,4
54 31 F phorate 4 MODERATE   +   3
55 28 M
Chlorpyripho
s 5 MODERATE  +  2,4
56 34 M
Chlorpyripho
s 8 SEVERE   +  3,7
57 21 M unknown 4 MODERATE  +  2,4
58 30 M
Chlorpyripho
s 5 MODERATE  ‐  ‐  +  5
59 40 M unknown 2 MILD  ‐  ‐  ‐  ‐ 1
60 33 F unknown 3 mild  +  ‐  ‐  ‐ 2,4
S.NO D1‐CPK‐MB
D3‐CPK‐
MB D7/DIS‐CPK‐MB S.ChE ‐D1
S.ChE‐
D3 S.ChE‐D 7/DIS MEC.VEC NO OF ICU STAY
1 24 22 24 3110 4214 4186            ‐
2 35 42  ‐ 750 612  ‐  + 4
3 29 32 31 2312 3216 3428  ‐
4 32 34 32 1980 2564 3196  ‐ 2
5 43 46 1512 890  ‐  + 3
6 39 42 41 970 1210 1790  + 9
7 28 32 34 1780 2348 2678  ‐ 2
8 34 35 34 1654 1470 1874   ‐ 3
9 18 17 17 2786 3675 4320  ‐ 1
10 22 23 22 2112 3126 2780  ‐ 2
11 23 21 21 3998 4690 4532  ‐ 2
12 34 36 35 1678 2310 3224  ‐ 3
13 39 45 42 480 598 670  + 8
14 31 29 26 1458 1780 2786  ‐ 2
15 25 25 23 2132 2980 3216  ‐ 2
16 23 21 21 3122 3452 3974  ‐ 2
17 48 47 45 798 1578 1764  + 8
18 17 20 19 3453 4512 4124  ‐ 1
19 34 36 35 2345 2348 2872  ‐ 3
20 31 33 32 2678 3248 3424  ‐ 3
21 29 31 29 2570 3120 3086  ‐ 2
22 32 32 31 2018 2676 2692  ‐ 3
23 23 21 22 3458 3890 3638  ‐ 2
24 37 39 39 2234 2118 1560  ‐ 3
25 44 45 44 1782 1340 1642  ‐ 4
26 23 25 26 4340 3890 3586  ‐ 1
27 37 46 45 1674 1560 1982  + 6
28 31 33 32 2784 2876 3128  ‐ 3
29 36 35 36 1982 2312 2874  ‐ 4
30 36 43 42 1120 912 1672  + 6
31 27 28 25 3210 3765 3429  ‐ 1
32 45  ‐  ‐ 450  ‐  ‐  + 4
33 35 32 31 3450 3421 2890  ‐ 1
34 42 43 39 2624 2131 2489  ‐ 4
35 29 31 30 2320 2497 3109  ‐ 2
36 30 31 28 2980 2390 2763  ‐ 1
37 37 42 40 1560 1239 1457  ‐ 3
38 44 47 43 986 678 980  + 9
39 36 41 49 780 430 1252  + 8
40 24 23 26 2442 2347 3428  ‐ 2
41 34 34 35 3210 2789 3120  + 5
42 43  ‐  ‐ 1260   ‐   + 1
43 36 38 37 2670 2872 2900  ‐ 3
S.NO D1‐CPK‐MB
D3‐CPK‐
MB D7/DIS‐CPK‐MB S.ChE ‐D1
S.ChE‐
D3 S.ChE‐D 7/DIS MEC.VEC NO OF ICU STAY
44 19 21 21 3490 4520 4128  ‐ 1
45 28 34 29 2100 1789 2642  ‐ 3
46 36 38 37 2680 2568 3124  ‐ 4
47 37 48   ‐ 1124 752   ‐  + 3
48 29 33 37 2168 2453 2876  ‐ 4
49 21 23 22 1560 2789 32100  ‐
50 19 21 20 1980 2542 2980  ‐ 2
51 22 23 21 3986 4023 3872  ‐ 1
52 23 21 24 2340 2978 3818  ‐ 3
53 45  ‐  ‐ 670  ‐  ‐  + 2
54 23 24 21 3120 3244 3642  ‐ 3
55 27 28 29 1980 2387 2982  ‐ 4
56 35 43 48 970 1670 2310  + 10
57 22 25 24 2670 3421 3228  ‐ 2
58 29 32 30 1547 2340 2976  ‐ 2
59 21 19 18 2875 3480 3258  ‐ 1
60 21 25 27 2345 2654 3214  ‐ 2
        We conclude that this study helps to predict the mortality in 
organophosphorous poisoning patients with investigations like ECG ,cardiac 
markers like CPK-MB which are readily available .These simple tools can be 
used effectively for early intervention and thereby intensifying the treatment 
which in the long run can reduce the mortality in OPC intoxicated  patients.
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